Cerebrospinal fluid levels of tumour necrosis factor-α and its receptors are not associated with disease progression in Alzheimer’s disease
The present study concludes that CSF TNFs do not serve as reliable or robust disease biomarkers of AD.
Authors
- Manal Aljuhani
Institutions
- Prince Sattam Bin Abdulaziz University (SA)
Publication Details
- Journal
- Frontiers in Aging Neuroscience
- Published
- 2025-04-14
- DOI
- https://doi.org/10.3389/fnagi.2025.1547185
- Citations
- 1
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- U.S. Department of Defense
- Alzheimer's Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Biogen
- University of Southern California
- Meso Scale Diagnostics
- Alzheimer's Disease Neuroimaging Initiative
- BioClinica
- Novartis Pharmaceuticals Corporation
- Northern California Institute for Research and Education
- Eisai
- Servier
- H. Lundbeck A/S
- IXICO
- National Institutes of Health
- Genentech
- Canadian Institutes of Health Research